journal article·2021-02-24Open access

Texture-Based Analysis of 18F-Labeled Amyloid PET Brain Images

Alexander P. Seiffert, Adolfo Gómez-Grande, Eva Milara, Sara Llamas-Velasco, Alberto Villarejo-Galende, Enrique J. Gómez, Patricia Sánchez-González

Applied Sciences· Volume 11· Issue 5

Abstract

Amyloid positron emission tomography (PET) brain imaging with radiotracers like [18F]florbetapir (FBP) or [18F]flutemetamol (FMM) is frequently used for the diagnosis of Alzheimer’s disease. Quantitative analysis is usually performed with standardized uptake value ratios (SUVR), which are calculated by normalizing to a reference region. However, the reference region could present high variability in longitudinal studies. Texture features based on the grey-level co-occurrence matrix, also called Haralick features (HF), are evaluated in this study to discriminate between amyloid-positive and negative cases. A retrospective study cohort of 66 patients with amyloid PET images (30 [18F]FBP and 36 [18F]FMM) was selected and SUVRs and 6 HFs were extracted from 13 cortical volumes of interest. Mann–Whitney U-tests were performed to analyze differences of the features between amyloid positive and negative cases. Receiver operating characteristic (ROC) curves were computed and their area under the curve (AUC) was calculated to study the discriminatory capability of the features. SUVR proved to be the most significant feature among all tests with AUCs between 0.692 and 0.989. All HFs except correlation also showed good performance. AUCs of up to 0.949 were obtained with the HFs. These results suggest the potential use of texture features for the classification of amyloid PET images.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Radiomics and Machine Learning in Medical Imaging · Medical Image Segmentation Techniques · Neurological Disease Mechanisms and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Biomedical Engineering and Telemedicine Centre, ETSI Telecomunicación, Center for Biomedical Technology, Universidad Politécnica de Madrid, 28040 Madrid, Spain

Department of Nuclear Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain

Department of Neurology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain

Group of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain

Biomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain

Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain

Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain

References (36)

Show source-provided references
1. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease10.1016/j.jalz.2018.02.018 ↗
2. Amyloid beta: Structure, biology and structure-based therapeutic development10.1038/aps.2017.28 ↗
3. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease10.1093/brain/awn016 ↗
4. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study10.1016/S1474-4422(12)70142-4 ↗
5. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: Phase 3 study10.1016/j.jalz.2015.02.004 ↗
6. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density10.1001/jamaneurol.2014.4144 ↗
7. Current radiotracers to image neurodegenerative diseases10.1186/s41181-019-0070-7 ↗
8. SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.010.2967/jnumed.116.174615 ↗
9. Technical considerations in brain amyloid PET imaging with 18F-Florbetapir10.2967/jnmt.115.156679 ↗
10. (2021, February 13). GE Healthcare VizamylTM, Flutemetamol F 18 Injection. Available online: http://www3.gehealthcare.com/~/media/documents/us-global/products/nuclear-imaging-agents_non-gatekeeper/clinicalproductinfo/vizamyl/gehealthcare-vizamyl-prescribing-information.pdf.
11. Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis10.1007/s00259-015-3228-x ↗
12. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: Statistical and pathological evaluation10.1093/brain/awv112 ↗
13. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects10.2967/jnumed.111.090340 ↗
14. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: Concordance with visual image reads10.2967/jnumed.114.142109 ↗
15. Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment10.1007/s00259-016-3359-8 ↗
16. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios10.2967/jnumed.114.148981 ↗
17. Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden10.1007/s00259-017-3666-8 ↗
18. Optimal reference region to measure longitudinal amyloid-b change with 18F-Florbetaben PET10.2967/jnumed.116.187351 ↗
19. White matter reference region in PET studies of 11C-Pittsburgh compound B uptake: Effects of age and amyloid-β deposition10.2967/jnumed.117.204271 ↗
20. Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid10.1038/s41598-020-70978-z ↗
21. Amyloid load: A more sensitive biomarker for amyloid imaging10.2967/jnumed.118.210518 ↗
22. Application of Haralick texture features in brain [18F]-florbetapir positron emission tomography without reference region normalization10.2147/CIA.S143307 ↗
23. Diagnostic and prognostic value of amyloid PET textural and shape features: Comparison with classical semi-quantitative rating in 760 patients from the ADNI-2 database10.1007/s11682-018-9833-0 ↗
24. Textural Features for Image Classification10.1109/TSMC.1973.4309314 ↗
25. Friston, K.J., Ashburner, J., Kiebel, S., Nichols, T., and Penny, W.D. (2006). Statistical Parametric Mapping: The Analysis of Funtional Brain Images, Academic Press. [1st ed.].
26. Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification10.1016/j.nicl.2018.07.013 ↗
27. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain10.1006/nimg.2001.0978 ↗
28. Implementation of a new parcellation of the orbitofrontal cortex in the automated anatomical labeling atlas10.1016/j.neuroimage.2015.07.075 ↗
29. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer’s disease10.1093/brain/awv229 ↗
30. Asymmetry of Fibrillar Plaque Burden in Amyloid Mouse Models10.2967/jnumed.120.242750 ↗
31. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities10.1088/0031-9155/60/14/5471 ↗
32. MRI features predict survival and molecular markers in diffuse lower-grade gliomas10.1093/neuonc/now256 ↗
33. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer10.1038/s41598-017-10371-5 ↗
34. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging10.1016/j.jalz.2012.10.007 ↗
35. Hosmer, D.W., Lemeshow, S., and Sturdivant, R.X. (2013). Assessing the Fit of the Model. Applied Logistic Regression, John Wiley & Sons.10.1002/9781118548387 ↗
36. Impact of MRI-based Segmentation Artifacts on Amyloid- and FDG-PET Quantitation10.2174/156720501304160325175855 ↗